Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb

The Istituti Clinici Scientifici Maugeri cardiology department in Bari is conducting research focused on heart failure, especially forms with preserved or mildly reduced ejection fraction, and the impact of renal dysfunction and systemic inflammation on outcomes.

• Evaluation of a dual SGLT2‑inhibitor and mineralocorticoid‑receptor antagonist therapy (balcinrenone/dapagliflozin) versus dapagliflozin alone.
• Assessment of a monthly anti‑inflammatory monoclonal antibody (ziltivekimab) added to standard care.
• Investigation of heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF).
• Study of patients with chronic heart failure and concurrent kidney impairment.

The trials aim to reduce cardiovascular death and heart‑failure events by testing whether the new combination drug or the anti‑inflammatory antibody can improve outcomes compared with existing therapy, offering potential advances for patients with complex heart‑failure phenotypes.